Skip to main content
Top
Published in: Rheumatology International 8/2010

01-06-2010 | Short Communication

Is rheumatoid factor still a superior test for the diagnosis of rheumatoid arthritis?

Authors: Usha Singh, Anjali Vishwanath, Pramod K. Verma, Nand K. Singh, Ram C. Shukla, Sangeeta Singh, Suman Singh, Gyanendra K. Sonkar

Published in: Rheumatology International | Issue 8/2010

Login to get access

Abstract

The diagnosis of rheumatoid arthritis (RA) is based primarily on the 1987 revised American College of Rheumatology criteria for RA, which considers mainly the clinical symptoms. But typical clinical symptoms of RA are not manifested completely in early disease course. On the other hand, appreciable advantages have been made in the therapeutic strategy of RA in the last decade and highly effective disease-modifying anti-rheumatic drugs are available now for the control of RA. The treatment strategy for the control of early RA is aggressive. Thus, a highly specific and early diagnostic marker is needed for the detection of RA. Our study is an attempt to see the role of anti-CCP2 antibody (claimed to be highly specific and early diagnostic tool) in the diagnosis of RA. We studied 119 cases of RA in terms of clinical symptoms, disease duration and various autoantibody [including rheumatoid factor (RF), anti-CCP2 antibody, antinuclear antibody, anti-dsDNA] and C-reactive protein status. All the tests were also performed in 26 age and sex-matched healthy controls. Estimation of antibodies was done by quantitative ELISA. IgM RF was positive in 47.89% cases (p value = 0.000), followed by IgG RF (42.01%, p = 0.000) and IgA RF (36.97%, p = 0.000). RF was positive in 64.7% RA cases (p value = 0.000) when all three isotypes were tested together. RF was also detected in one healthy control. In 92 cases, anti-CCP2 Ab was done, hence other data were analyzed further in 92 cases only. Anti-CCP2 Ab was positive (cut-off = 15.0 U/ml) in only 50% RA patients but none of the healthy controls was positive for it. Swelling of joints was seen in 82.6% anti-CCP2 Ab positive cases (p value = 0.092) when compared with anti-CCP2 Ab negative cases (67.4%) while among RF positive cases, only 65.4% ((p value = 0.010) cases had swelling of joints. Out of 39 RA cases presenting with disease duration less than 1 year, only 48.71% patients were anti-CCP2 Ab positive while RF was positive in 61.53% patients. Utility of various combined autoantibody tests revealed that if one does all isotypes of RF (IgG, IgA and IgM) only, then 64.7% RA cases can be diagnosed and if anti-CCP2 Ab is added to it, the sensitivity increases to 75.56%. Thus, our study concludes that anti-CCP2 Ab is not a sensitive test for the diagnosis of RA neither it is useful in early diagnosis of RA, but it increases the sensitivity if added with all RF isotypes.
Literature
1.
go back to reference Vasishta A (2002) Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies. Am Clin Lab 21(7):34–36PubMed Vasishta A (2002) Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies. Am Clin Lab 21(7):34–36PubMed
2.
go back to reference Kvien TK (2002) Epidemiology of disability in rheumatoid arthritis. Rheumatology (Oxford) 41:121–123CrossRef Kvien TK (2002) Epidemiology of disability in rheumatoid arthritis. Rheumatology (Oxford) 41:121–123CrossRef
3.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRefPubMed
4.
go back to reference Visser H, Cessie Le, Vos K, Breedveld FC, Hazes JM (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357–365CrossRefPubMed Visser H, Cessie Le, Vos K, Breedveld FC, Hazes JM (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357–365CrossRefPubMed
5.
go back to reference Machold KP, Stamm TA, Eberl GJ, Nell VK, Dunky A, Uffmann M, Smolen JS (2002) Very recent onset arthritis- clinical, laboratory and radiological findings during the first year of disease. J Rheumatol 29:2278–2287PubMed Machold KP, Stamm TA, Eberl GJ, Nell VK, Dunky A, Uffmann M, Smolen JS (2002) Very recent onset arthritis- clinical, laboratory and radiological findings during the first year of disease. J Rheumatol 29:2278–2287PubMed
6.
go back to reference Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS (2002) Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61:290–297CrossRefPubMed Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS (2002) Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61:290–297CrossRefPubMed
7.
go back to reference Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ (2003) Influence of disease modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48:46–53CrossRefPubMed Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ (2003) Influence of disease modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48:46–53CrossRefPubMed
8.
go back to reference Landewe RB (2003) The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 48:1–5CrossRefPubMed Landewe RB (2003) The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 48:1–5CrossRefPubMed
9.
go back to reference Lard LR, Visser H, Speyer I, van der Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, Hazes JM (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111:446–451CrossRefPubMed Lard LR, Visser H, Speyer I, van der Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, Hazes JM (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111:446–451CrossRefPubMed
10.
go back to reference Lisse JR (1993) Does rheumatoid factor always mean arthritis? Postgrad Med 94(6):133–134, 139PubMed Lisse JR (1993) Does rheumatoid factor always mean arthritis? Postgrad Med 94(6):133–134, 139PubMed
11.
go back to reference Hoet RM, van Venrooij WJ (1992) The antiperinuclear factor (APF) and antikeratin antibodies (AKA) in rheumatoid arthritis. In: Smolen JS, Kalden JR, Maini RN (eds) Rheumatoid arthritis. Springer, Berlin, pp 299–318 Hoet RM, van Venrooij WJ (1992) The antiperinuclear factor (APF) and antikeratin antibodies (AKA) in rheumatoid arthritis. In: Smolen JS, Kalden JR, Maini RN (eds) Rheumatoid arthritis. Springer, Berlin, pp 299–318
12.
go back to reference Schellekens GA, Visser H, de Jong BAW, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163CrossRefPubMed Schellekens GA, Visser H, de Jong BAW, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163CrossRefPubMed
13.
go back to reference Bizzaro N, Mazzanti G, Tonutti E, Vellalta D, Tozzoli R (2001) Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47:1089–1093PubMed Bizzaro N, Mazzanti G, Tonutti E, Vellalta D, Tozzoli R (2001) Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47:1089–1093PubMed
14.
go back to reference Girbal NE, Durieux JJ, Arnaud M, Dalbon P, Sebbag M et al (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 162(1):585–594 Girbal NE, Durieux JJ, Arnaud M, Dalbon P, Sebbag M et al (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 162(1):585–594
15.
go back to reference Van Venrooij WJ, Van Beers JJBC, Pruijn GJM (2008) Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 1143:268–285CrossRefPubMed Van Venrooij WJ, Van Beers JJBC, Pruijn GJM (2008) Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 1143:268–285CrossRefPubMed
16.
go back to reference Hill JA, Southwood S, Sette A, Jevinkar AM, Bell DA, Cairns E (2003) Cutting edge: the conversion of arginine to citrulline allows for a high affinity peptide interaction with the rheumatoid arthritis associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171:538–541PubMed Hill JA, Southwood S, Sette A, Jevinkar AM, Bell DA, Cairns E (2003) Cutting edge: the conversion of arginine to citrulline allows for a high affinity peptide interaction with the rheumatoid arthritis associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171:538–541PubMed
17.
go back to reference Vallbracht I, Rieber J, Oppermann M et al (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084CrossRefPubMed Vallbracht I, Rieber J, Oppermann M et al (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084CrossRefPubMed
18.
go back to reference Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870–874CrossRefPubMed Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870–874CrossRefPubMed
19.
go back to reference Pinheiro GC, Scheinberg MA, Aparecida DS, Maciel S (2003) Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med 139:234–235PubMed Pinheiro GC, Scheinberg MA, Aparecida DS, Maciel S (2003) Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med 139:234–235PubMed
20.
go back to reference van Boekel MA, Vossenaar ER, van Den Hoogen FH, van Venrooij WJ (2001) Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 4:87–93CrossRefPubMed van Boekel MA, Vossenaar ER, van Den Hoogen FH, van Venrooij WJ (2001) Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 4:87–93CrossRefPubMed
21.
go back to reference Meyer O (2003) Evaluating inflammatory joint disease: how and when can autoantibodies help? Joint Bone Spine 70:433–447CrossRefPubMed Meyer O (2003) Evaluating inflammatory joint disease: how and when can autoantibodies help? Joint Bone Spine 70:433–447CrossRefPubMed
22.
go back to reference Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C et al (2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2:236–243CrossRefPubMed Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C et al (2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2:236–243CrossRefPubMed
23.
go back to reference Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (oxford) 41:809–814CrossRef Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (oxford) 41:809–814CrossRef
24.
go back to reference de Rycke L, Peene I, Hoffman IEA, Kruithof E, Union A, Meheus L et al (2004) Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 63:1587–1593CrossRefPubMed de Rycke L, Peene I, Hoffman IEA, Kruithof E, Union A, Meheus L et al (2004) Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 63:1587–1593CrossRefPubMed
25.
go back to reference Dubucquoi S, Solau-Gervais E, Lefranc D, Marquerie L, Sibilia J et al (2004) Evaluation of anti-citrullinated fillagrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 63:415–419CrossRefPubMed Dubucquoi S, Solau-Gervais E, Lefranc D, Marquerie L, Sibilia J et al (2004) Evaluation of anti-citrullinated fillagrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 63:415–419CrossRefPubMed
26.
go back to reference Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201CrossRefPubMed Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201CrossRefPubMed
27.
go back to reference Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089CrossRefPubMed Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089CrossRefPubMed
28.
go back to reference van Venrooij WJ, Zendman AJ, Pruijn GJ (2006) Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 6:37–41CrossRefPubMed van Venrooij WJ, Zendman AJ, Pruijn GJ (2006) Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 6:37–41CrossRefPubMed
29.
go back to reference Vallbracht I, Helmke K (2005) Additional diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Autoimmun Rev 4(6):389–394CrossRefPubMed Vallbracht I, Helmke K (2005) Additional diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Autoimmun Rev 4(6):389–394CrossRefPubMed
30.
go back to reference Ranatapaa-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749CrossRef Ranatapaa-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749CrossRef
31.
go back to reference Nielen MM, van Schaardenberg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386CrossRefPubMed Nielen MM, van Schaardenberg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386CrossRefPubMed
32.
go back to reference Kroot EJ, de Jong BA, Van Leeuwen MA, van den Hoogen FH, van’t Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835CrossRefPubMed Kroot EJ, de Jong BA, Van Leeuwen MA, van den Hoogen FH, van’t Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835CrossRefPubMed
33.
go back to reference Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A et al (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120–126CrossRefPubMed Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A et al (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120–126CrossRefPubMed
34.
go back to reference Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B et al (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 years follow-up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749CrossRefPubMed Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B et al (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 years follow-up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749CrossRefPubMed
Metadata
Title
Is rheumatoid factor still a superior test for the diagnosis of rheumatoid arthritis?
Authors
Usha Singh
Anjali Vishwanath
Pramod K. Verma
Nand K. Singh
Ram C. Shukla
Sangeeta Singh
Suman Singh
Gyanendra K. Sonkar
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 8/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1338-0

Other articles of this Issue 8/2010

Rheumatology International 8/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.